Mimedx (MDXG) Cash from Operations Growth (5y) (2016 - 2026)

Mimedx (MDXG) Cash from Operations Growth (5y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Mimedx 635.35 Mn 475.58 Mn 41.62 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 17.93%
Dec 31, 2025 34.68%
Sep 30, 2025 52.88%
Jun 30, 2025 46.10%
Mar 31, 2025 19.45%
Dec 31, 2024 22.97%
Sep 30, 2024 53.44%
Jun 30, 2024 59.25%
Mar 31, 2024 19.05%
Dec 31, 2023 -6.30%
Sep 30, 2023 30.99%
Jun 30, 2023 -10.37%
Mar 31, 2023 -43.23%
Dec 31, 2022 -27.10%
Sep 30, 2022 -44.34%
Jun 30, 2022 -17.32%
Mar 31, 2022 -24.25%
Dec 31, 2021 -22.48%
Sep 30, 2021 17.34%
Jun 30, 2021 -26.15%